Summary
77 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 113% a year over the last 3 years.
- Out of every 100 SEK of revenue, 15 SEK is left as net profit.
- It earns 14 SEK a year on every 100 SEK of invested capital.
What to watch
- The share price is above the Bulios Fair Price.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 32.8 SEK for 1 SEK of yearly profit. Over the last five years it was 47.9 SEK on average.
Valuation in detailIs it growing?
Yes, fastRevenue (SEK)
Diluted EPS (SEK)
- Analyst estimate
Revenue grew by 16% a year over 5 years. Over the last 3 years it grew by 17% a year. Earnings per share grew by 113% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 SEK of revenue goes
- Cost of sales 26 SEK
- Research and development 20 SEK
- Sales and administration 35 SEK
- Taxes and other 3.0 SEK
- Net profit 15 SEK
Net profit, industry median (Medical - Healthcare Information Services) 5.3 SEK
Out of every 100 SEK of revenue, 15 SEK is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 1.2 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, stretched- Yield
- 2.17%
- Paid out of profit
- 71%
- Raised in a row
- 1 year
You receive $0.43 per share a year. The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.